Drugs / rhASA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00418561 | Jan 2007 → Mar 2008 | metachromatic leukodystrophy, late infantile form | Shire | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhASA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00418561 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human ASA” PMID 33332761 ↗ Dec 2020 |
| Route | Intravenous | “Intravenous infusion 25 U/kg as a single dose - hereafter 50 U/kg every other week for 26 weeks” NCT00418561 ↗ |